[Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):247-250. doi: 10.3760/cma.j.issn.0253-2727.2023.03.012.

[Article in Chinese]

Authors

R Jiang¹, L M J Dai¹, Y Q Sha¹, Y Xia¹, Y Miao¹, S C Qin¹, W Wu¹, J Y Qiu², H L Bi², L Wang¹, L Fan¹, W Xu¹, J Y Li¹, H Y Zhu¹

Affiliations

¹ Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
² Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.

PMID: 37356988
PMCID: PMC10119717
DOI: 10.3760/cma.j.issn.0253-2727.2023.03.012

No abstract available

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Rituximab / therapeutic use
Sulfonamides / therapeutic use

Substances

Rituximab
venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Antineoplastic Agents

Grants and funding

基金项目：国家自然科学基金（82170166、82100207）；江苏省人民医院青年拔尖人才专项基金（YNRCQN035）